AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Morgan Stanley Assigns Equal Weight Rating to Incyte with $73 Price Target
ByAinvest
Friday, Jul 4, 2025 7:22 am ET1min read
Morgan Stanley assumed coverage of Incyte with an Equal Weight rating and a price target of $73. The firm sees a positive outlook for key data updates expected this year for mCALR and JAK2V617Fi in Myelofibrosis, and Phase II data for povorcitinib in asthma in the second half of 2025, which could further prove the potential for povo beyond hidradenitis suppurativa.
Sign up for free to continue reading
Unlimited access to AInvest.com and the AInvest app
Follow and interact with analysts and investors
Receive subscriber-only content and newsletters
or
By continuing, I agree to the
Market Data Terms of Service and Privacy Statement
Already have an account?
Aime Insights
How might the performance of Shopify affect the broader market trends?
How might the upcoming earnings report of AMD influence investor sentiment?
What are the potential implications of the US Senate's failure to pass a temporary funding bill on the broader market?
How might Michael Burry's short position on Palantir and NVIDIA affect the AI sector?
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet